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Azaadamantane Benzamide 5-HT4 Agonists: Gastrointestinal Prokinetic SC-54750 
Daniel P. Becker*, Daniel L. Flynn, Robert L. Shone, and Gary Gullikson 
Department of Medicinal Chemistry, Pfizer Research & Development, 4901 Searle Parkway, Skokie, IL 60077 
Aazaadamantanone 1 was converted to a series of aminoazaadamantane benzamides 9a-d which were profiled for 
serotonin receptor activity.  Aminomethylazaadamantane SC-54750 is a potent 5-HT4 agonist and 5-HT3 antagonist 
with in vivo efficacy in gastroparesis models and also inhibits cisplatin-induced emesis. 
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5-HT3 IC50 = 3.5 nM
canine gastroparesis ED80 = 0.62 mpk ig
cisplatin emesis ID50 = 0.3 mpk iv
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Abstract—Azaadamantanone 1 was converted to a series of aminoazaadamantane benzamides 
9a-d which were profiled for serotonin receptor activity.  Aminomethylazaadamantane SC-
54750 is a potent 5-HT4 agonist and 5-HT3 antagonist with in vivo efficacy in gastroparesis 
models and also inhibits cisplatin-induced emesis. 
 
Serotonin (5-hydroxytryptamine, 5-HT) functions as both a hormone and a neurotransmitter, 
controlling a host of central and peripheral effects via a number of receptors.1 The 5-HT4 
receptor was discovered by Clark2 and Bockaert3 in the brain and gut, respectively, and is 
expressed in a wide variety of tissues including brain, heart, bladder, gut and kidney.4,5  Initial 
demonstration that renzapride and cisapride could enhance contractile activity at neuronal 5-HT4 
receptors in the guinea pig ileum was made by Craig and Clarke.6  It was later demonstrated that 
5-HT4 receptors mediate the relaxation of smooth muscle of the inner muscularis mucosae of rat 
esophagus7 and also the cholinergic stimulation of the ascending colon of the guinea pig.8  The 
5-HT4 partial agonist tegaserod (SDZ HTF 919) was approved in 2002 for the treatment of 
constipation-predominant irritable bowel syndrome (IBS).9   Tegaserod showed a clear effect on 
the total colonic transit time in healthy subjects, and a significant improvement in patients with 
constipation-predominant IBS in a phase III trial.10  Cisapride (PrepulsidTM) had been marketed 
for motility disorders11 but was withdrawn due to potent hERG block and QT prolongation.12  An 
excellent review of the 5-HT4 receptor and key ligands was recently published.13  
 
We have investigated a number of conformationally-constrained tertiary amine derivatives as 
serotonin 5-HT4 agonist and antagonists, and as 5-HT3 antagonists.14  We previously reported the 
5-HT4 activity of pyrrolizidine SC-53116,15 the first selective 5-HT4 agonist, and SC-53606, a 
selective 5-HT4 antagonist.16  We have also reported the blended 5-HT3/5-HT4 activity of 
azanoradamantane SC-5249117, which is a mixed 5-HT4 agonist/5-HT3 antagonist, and of a 
series of meso-azanoradamantanes.18  Azaadamantanes are theoretically interesting molecules19 
with many potential uses20 and have the advantage that they lack chirality.  Herein we detail our 
investigation of aminoazaadamantane benzamides and disclose the aminomethylazaadamantane 
clinical candidate SC-54750, a selective 5-HT4 agonist with excellent in vivo pharmacology 
demonstrating utility as a gastrointestinal prokinetic agent. 
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We previously reported the synthesis of the individual syn and anti aminoazaadamantanes 2 and 
3 via 1-azatricyclo[3.3.1.13,7]decan-4-one 1 (Scheme 1).21  Homologation of 1 was accomplished 
utilizing van Leusen’s reductive alkylation22 of 1 with tosylmethyl isocyanide (TosMIC) to give 
the nitriles 4 and 5 (Scheme 2), which were separated by chromatography on silica gel eluting 
with MeOH(NH3)/CHCl3.  Reduction of the nitriles independently with lithium aluminum 
hydride gave the distillable amines 6 and 7, which suffered ≤ 2% epimerization in the reduction 
procedure.  Benzamide coupling of the aminoazaadamantanes with 4-amino-5-chloro-2-methoxy 
benzoic acod 8 utilizing carbonyldiimidazole (CDI) as the coupling reagent gave the requisite 
aminoazaadamantane benzamides which were treated with hydrogen chloride to afford the 
crystalline monohydrochloride salts 9a-d (Scheme 3). 
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Scheme 1. Preparation of epimeric aminoazaadamantanes 2 and 3. 
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Scheme 2. Synthesis of epimeric aminomethylazaadamantanes 6 and 7. 
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Scheme 3. Coupling procedure to afford aminoazaadamantane benzamides 9a-d. 
 
As seen in Table 1, anti-aminoazaadamantane 9b is twice as potent as the corresponding syn-
isomer 9a in 5-HT4 agonism in the rat tunica muscularis mucosae (TMM) assay,23 and the anti-
isomer is an order of magnitude more potent in 5-HT4 receptor binding24 (Ki = 57 nM vs. > 500 
nM).   Anti-aminoazaadamantane 9b is also substantially (37X) more potent than the syn-isomer 
in 5-HT3 binding.25  This greater potency for the 5-HT3 receptor is also revealed in the Bezold-
Jarisch reflex26 in mice, where 9b affords > 50% inhibition down to 0.03 mpk ip, whereas 9a is 
inactive at 3 mpk.  With the homologated aminomethylazaadamantanes, it is the syn-isomer that 
is more potent at both receptors.  Syn-isomer 9c (SC-54750) is 5X more potent than anti-isomer 
9d as an agonist at the 5-HT4 receptor in the TMM assay (73.6 nM vs. 545 nM) and is 5X more 
potent in binding at the 5-HT3 receptor (Ki = 25.4 nM vs. 143.7 nM).  This differential in 5-HT3 
potency is reflected in the greater potency of inhibition of the 5-HT3 receptor by SC-54750 in the 
von Bezold-Jarisch reflex assay, with 9c affording >50% inhibition down to 0.1 mpk versus 9d, 
which is inactive at 1 mpk. 
 
Aminomethylazaadamantane SC-54750 is highly selective versus other monoamine receptors,27 
as are the other azaadamantane derivatives, as summarized in Table 2, with no affinity detected 
(IC50 > 10,000 nM) for serotonin 5-HT1 or 5-HT2 receptors, dopamine D1 or D2 receptors, α1 or 
α2 adrenergic receptors, or β-adrenergic receptors.  SC-54750 is quite similar to SC-52491 in 
potency for both 5-HT4 and 5-HT3 receptors and possesses exquisite selectivity versus other 
monoamine receptors.  Cisapride, in contrast, binds to D2 and α1 receptors, and is exceptionally 
potent for the 5-HT2 receptor (IC50 = 6.1 nM). 
 Table 1. In vitro serotonergic activity of aminoazaadamantane benzamides 9a-d 
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Entry 
(stereo) 
n 5-HT4 Binding 
Ki, nM (SEM) 
5-HT4 agonism 
in rat TMM 
EC50 (nM) 
5-HT3 
Binding 
Ki (nM) 
Bezold-Jarisch Reflex, 
5-HT3 antagonism, 
% inhib at dose (mpk ip) 
9a 
(syn) 
0 > 500 538 336 85% at 10 
0% at 3 
9b 
(anti) 
0 57 262 9 
 
86% at 10 
81% at 3 
75% at 1 
70% at 0.3 
64% at 0.1 
61% at 0.03 
9c 
(syn) 
SC-54750 
1 51 
 
73.6 25.4 88% at 10 
82% at 8 
82% at 1 
75% at 0.3 
60% at 0.1 
0% at 0.03 
9d 
(anti) 
1 ND 545 143.7  85% at 10 
82% at 3 
0% at 1 
 
 
 
 
 
 
Table 2. Receptor profiling of azaadamantane benzamides 9a-d and cisapride:  ED50 [5-HT4] or IC50 [all others], nM 
 
 
 
 
Entry 5-HT4 5-HT3 5-HT1 5-HT2 D1 D2 α1 α2 β 
9a 538 672 >10K 1800 >10K >10K >10K 6400 >10K 
9b 262 18 >10K >10K >10K >10K >10K >10K >10K 
9c SC-54750 73.6 3.5 >10K >10K >10K >10K >10K >10K >10K 
9d 545 11 ND ND ND >10K ND ND ND 
SC-52491 51.3 2.3 >10K >10K >10K >10K >10K >10K >10K 
Cisapride 54.7 134 >10K 6.1 1700 227 30 4500 >10K 
SC-54750 was selected for further study and was found to be a potent stimulator of gastric 
emptying in rats, with comparable activity that is observed for oral dosing when given at 3X the 
iv dose.  SC-54750 is a potent stimulator of gastric contractile activity in fasted dogs that were 
surgically implanted with strain gauges.28  SC-54750 is comparable to cisapride in eliciting 
antral contractions, with intestinal myoelectric spike burst (contractile) activity that is stimulated 
in the same dose range. 
 
The dosages responsible for eliciting gastric antral contractile responses in dogs corresponded 
well to the gastric emptying profiles.  In a canine gastroparesis model of 5-HT4 agonism29 SC-
54750 is potent and efficacious in restoring normal motility, exhibiting an EC50 of 0.03 mg/kg iv 
and an ED80 of 0.62 mg/kg, ig.  The 5-HT3 antagonism of SC-54750 gives rise to effective 
inhibition of cisplatin-induced emesis in dogs, with an ID50 of 0.3 mg/kg, iv.  The compound was 
orally active in this model as well. 
 
SC-54750 is an achiral gastrointestinal prokinetic benzamide which compares quite favorably 
with cisapride and SC-52491.  SC-54750 is a potent 5-HT4 agonist and 5-HT3 receptor 
antagonist with excellent selectivity.  It is orally active in stimulating gastrointestinal motility 
and in blocking cisplatin-induced emesis. 
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